Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care

Background/Objectives: As survival among people living with HIV (PLWH) improves, metabolic and age-related comorbidities have become increasingly important. This narrative review evaluates the evolving role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in HIV care, distinguishing established benefits from emerging evidence across metabolic, hepatic, cardiovascular, inflammatory, immune, neurocognitive, ageing, and body-composition outcomes. Methods: PubMed was searched for English-language publications from January 2016 to July 2026. Randomised trials, interventional and observational studies, case reports, reviews, and meta-analyses were considered. Two authors independently extracted study characteristics and outcomes. Studies were grouped by parent trial or cohort and synthesised narratively without statistical pooling. Results: GLP-1 RAs, particularly semaglutide, show reduced body weight and visceral adiposity and improved glycaemic control in PLWH, although the range of weight loss varied across studies. Benefits were also observed for liver fat; triglycerides; very-low-density lipoprotein and remnant lipoproteins; and selected inflammatory markers, particularly high-sensitivity C-reactive protein. Evidence for immune effects, neurocognitive improvement, biological ageing, and preservation of muscle mass and function remains limited or inconsistent. Treatment was generally well tolerated, with gastrointestinal symptoms most frequently reported. Clinically significant interactions with contemporary antiretroviral therapy have not been identified, although dedicated interaction studies remain limited. Conclusions: GLP-1 RAs may have a role in HIV care extending beyond weight reduction and glucose control. Larger, independent, longer-term studies are needed to clarify broader clinical benefits, mechanisms, long-term safety, and interactions with antiretroviral therapy.

Authors

Institutions

Publication Details

Journal
Metabolites
Published
2026-11-16
DOI
https://doi.org/10.3390/metabo16110894
Primary Topic
HIV-related health complications and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care

Rami Hammoud, Constantinos Tsioutis, Danny Alon-Ellenbogen, Najwa F Mourad
Metabolites
HIV-related health complications and treatments
article

Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care

Rami Hammoud, Constantinos Tsioutis, Danny Alon-Ellenbogen, Najwa F Mourad
article en

Abstract

Background/Objectives: As survival among people living with HIV (PLWH) improves, metabolic and age-related comorbidities have become increasingly important. This narrative review evaluates the evolving role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in HIV care, distinguishing established benefits from emerging evidence across metabolic, hepatic, cardiovascular, inflammatory, immune, neurocognitive, ageing, and body-composition outcomes. Methods: PubMed was searched for English-language publications from January 2016 to July 2026. Randomised trials, interventional and observational studies, case reports, reviews, and meta-analyses were considered. Two authors independently extracted study characteristics and outcomes. Studies were grouped by parent trial or cohort and synthesised narratively without statistical pooling. Results: GLP-1 RAs, particularly semaglutide, show reduced body weight and visceral adiposity and improved glycaemic control in PLWH, although the range of weight loss varied across studies. Benefits were also observed for liver fat; triglycerides; very-low-density lipoprotein and remnant lipoproteins; and selected inflammatory markers, particularly high-sensitivity C-reactive protein. Evidence for immune effects, neurocognitive improvement, biological ageing, and preservation of muscle mass and function remains limited or inconsistent. Treatment was generally well tolerated, with gastrointestinal symptoms most frequently reported. Clinically significant interactions with contemporary antiretroviral therapy have not been identified, although dedicated interaction studies remain limited. Conclusions: GLP-1 RAs may have a role in HIV care extending beyond weight reduction and glucose control. Larger, independent, longer-term studies are needed to clarify broader clinical benefits, mechanisms, long-term safety, and interactions with antiretroviral therapy.

MetabolitesVol. 16(11)
University of Nicosia (CY), European University Cyprus (CY)
HIV-related health complications and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon